Department of Gastroenterology, Allergology and Pediatrics, Polish Mother's Memorial Hospital-Research Institute, Lodz 93-338, Poland.
Division of Anatomy, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-367, Poland.
Can J Gastroenterol Hepatol. 2021 Apr 24;2021:6665697. doi: 10.1155/2021/6665697. eCollection 2021.
Immunological disorders, increased oxidative stress, and damage to the epithelial barrier play an important role in the pathogenesis of inflammatory bowel diseases (IBDs). In the treatment of patients with Crohn's disease (CD) and ulcerative colitis (UC), it is increasingly common to use biological drugs that selectively affect individual components of the inflammatory cascade. However, administering the medicines currently available does not always result in obtaining and maintaining remission, and it may also lead to the development of resistance to a given agent over time. Metallothioneins (MTs) belong to the group of low molecular weight proteins, which, among others, regulate the inflammation and homeostasis of heavy metals as well as participating in the regulation of the intensity of oxidative stress. The results of the studies conducted so far do not clearly indicate the role of MTs in the process of inflammation in patients with IBD. However, there are reports that suggest the possibility of using MTs as a potential target in the treatment of this group of patients.
免疫紊乱、氧化应激增加和上皮屏障损伤在炎症性肠病 (IBD) 的发病机制中起重要作用。在克罗恩病 (CD) 和溃疡性结肠炎 (UC) 患者的治疗中，越来越多地使用选择性影响炎症级联反应中单个成分的生物药物。然而，施用目前可用的药物并不总是导致获得和维持缓解，并且随着时间的推移，它也可能导致对给定药物产生耐药性。金属硫蛋白 (MT) 属于低分子量蛋白组，除其他外，它调节炎症和重金属的动态平衡，以及参与调节氧化应激的强度。迄今为止进行的研究结果并未明确表明 MT 在 IBD 患者炎症过程中的作用。然而，有报道表明，MT 有可能作为这组患者治疗的潜在靶点。
